Go Deep
Puma Biotechnology, Inc.
Puma Biotechnology, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 19,856 | 19.8 | 3.77 | 0.04 | 963.77 |
| Oct 2026 | 19,802 | 20.0 | 3.80 | 0.04 | 968.46 |
| Oct 2026 | 19,688 | 20.2 | 3.92 | 0.04 | 998.99 |
| Oct 2026 | 20,144 | 19.3 | 3.66 | 0.04 | 931.05 |
| Oct 2026 | 19,896 | 20.0 | 3.80 | 0.04 | 968.08 |
| Oct 2026 | 19,591 | 21.1 | 4.01 | 0.04 | 1,020.22 |
| Oct 2026 | 19,564 | 21.4 | 4.06 | 0.04 | 1,030.95 |
| Oct 2026 | 19,513 | 22.1 | 4.20 | 0.04 | 1,062.84 |
Puma Biotechnology, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 56,502,000.0 | 44,814,000.0 | 75,453,000.0 | 54,475,000.0 |
| Net Profit | 8,189,000.0 | -3,753,000.0 | 13,438,000.0 | 8,844,000.0 |
| EPS | 0.2 | -0.1 | 0.3 | 0.2 |
Puma Biotechnology, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 228,371,000.0 | 230,468,000.0 | 235,637,000.0 | 228,031,000.0 | — |
| Net Profit | 31,111,000.0 | 30,278,000.0 | 21,591,000.0 | 2,000.0 | — |
| EPS | 0.6 | 0.6 | 0.5 | 0.0 | — |
Puma Biotechnology, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 216,302,000.0 | 213,333,000.0 | 230,528,000.0 | 222,059,000.0 | — |
| Total Liabilities | 85,962,000.0 | 121,208,000.0 | 177,086,000.0 | 200,451,000.0 | — |
| Total Equity | 130,340,000.0 | 92,125,000.0 | 53,442,000.0 | 21,608,000.0 | — |
Owes vs Owns
Puma Biotechnology, Inc. owed $0.28 for every $1 it owned in Jun 2026, down from $0.90 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.28× | 0.40× | 0.57× | 0.77× | 0.90× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Puma Biotechnology, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 45.1%Receivables 24.8%Inventory 2.5%Fixed assets (tangible) 2.6%Intangible assets 19.1%Other assets 5.8%
How it's funded — Dec 2025
Short-term debt 10.4%Long-term debt 2.2%Payables 2.3%Other liabilities 24.8%Shareholders' equity 60.3%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 97.5 | 101.0 | 95.9 | 81.1 |
| Receivables | 53.7 | 32.0 | 47.8 | 42.3 |
| Inventory | 5.5 | 8.7 | 7.1 | 4.5 |
| Fixed assets (tangible) | 5.6 | 5.1 | 8.6 | 12.5 |
| Intangible assets | 41.4 | 51.1 | 60.9 | 70.6 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 12.7 | 15.4 | 10.2 | 11.1 |
| Liabilities & equity | ||||
| Short-term debt | 22.5 | 45.3 | 34.0 | 4.1 |
| Long-term debt | 4.7 | 21.7 | 65.7 | 98.3 |
| Payables | 5.1 | 5.5 | 6.9 | 6.4 |
| Other liabilities | 53.7 | 48.7 | 70.5 | 91.6 |
| Shareholders' equity | 130.3 | 92.1 | 53.4 | 21.6 |
| Net tangible assets | 88.9 | 41.0 | -7.4 | -49.0 |
Puma Biotechnology, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | 41,802,000.0 | 38,918,000.0 | 27,009,000.0 | -15,827,000.0 | — |
| Investing Activities | -36,188,000.0 | -20,438,000.0 | -19,125,000.0 | 7,104,000.0 | — |
| Financing Activities | -45,198,000.0 | -33,846,000.0 | 0.0 | 12,223,000.0 | — |